Your session is about to expire
← Back to Search
Mavodelpar for Mitochondrial Myopathy (STRIDE Trial)
STRIDE Trial Summary
This trial will test if a new drug, REN001, is effective and safe for treating PMM (a 24-week study).
- Primary Mitochondrial Myopathy
STRIDE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSTRIDE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.STRIDE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have muscle pain during exercise or when active.You are 18 years or older and have a type of muscle disease called primary mitochondrial myopathy (PMM), as defined by a group of experts.
- Group 1: Mavodelpar
- Group 2: Matched placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the research team currently enrolling new participants?
"Clinicaltrials.gov confirms that recruitment for this medical trial is still ongoing since it's initial posting on May 21st 2021 and subsequent editing in December 7th 2022."
What is the geographic scope of this experiment?
"Patients can enrol in this study at several locations, including the University of Texas McGovern Medical School in Houston and UT South Western located in Dallas. Moreover, there are 13 other sites across Alberta and California that are also participating."
Is this an innovative research project?
"Since 2021, REN001 has been studied by the pharmaceutical company known as Reneo Pharma Ltd. The initial study in 2021 featured 200 participants and concluded with successful Phase 2 approval of the medication. Currently, only one active clinical trial involving this drug is being run by Reneo Pharma Ltd."
How many participants are included in this clinical experiment?
"The clinical trial necessitates 200 participants that comply with the outlined inclusion criteria. Those hoping to volunteer can do so from University of Texas McGovern Medical School in Houston, and UT South Western in Dallas, Alberta."
Could you elaborate on the research that has been done with REN001 in prior experiments?
"The REN001 medication was first explored in 2021 at A.O.U Policlinico di Messina U.O.C Neurologia e Malattie Neuromuscolari, and since then a total of 18352 clinical trials were completed with 1 still recruiting patients presently - primarily based out of Houston, Texas."
What risks does REN001 pose to human health?
"With Phase 2 scientific evidence suggesting safety, REN001 has been assigned a score of 2 on our risk assessment scale. Nevertheless, there is no corresponding data that verifies its efficacy."
Share this study with friends
Copy Link
Messenger